EGFR and non-small cell lung carcinoma: To combat resistance to EGFR inhibitors in NSCLC, He et al. [131] co-encapsulated EGFR and integrin αvβ3 inhibitors, namely erlotinib and cilengitide, respectively, in MPEG-PLA [methoxy poly (ethylene glycol)-poly (lactide)] NPs.